This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As many of you know, hospitals and health systems have emerged as significant participants in the specialty pharmacy industry. A new American Society of Hospital Pharmacists (ASHP) survey provides fresh insights into these specialty pharmacies. I then highlight how hospitals steer prescriptions to their internal specialty pharmacies.
However, buy-and-bill appears to have rebounded substantially at hospitals. As I explain below, this resurgence likely reflects the success of vertically-integrated hospital/specialty pharmacy/physician mega-systems against the large insurer/PBM/specialty pharmacy/provider mega-organizations. d/b/a Drug Channels Institute.
healthcare system Trick Play : Patients and plans get sacked by a gross spending-to-net bubble Defensive line : A comeback for pharmacy students Offensive line : Apexus dances in the end zone, while a 340B hospital tackles a patient Plus, Super Antonio runs downfield in the Mushroom Kingdom. How Mark Cuban would quarterback the U.S.
Let’s turn up the heat with these sizzling news bites straight from the Drug Channels grill: SaveonSP gets sued Thoughts on the Medicaid accumulator rule opinion CVS buys AmerisourceBergen’s specialty pharmacy Fresh data on hospitals’ cancer drug profiteering Plus, Dr. Glaucomflecken explains Aetna’s prior authorization policies.
pharmacy industry—act as contract pharmacies for the hospitals and federal grantees that participate in the 340B program. Federal grantees are aligned primarily with the vertically intergated organizations' retail pharmacies, while hospitals rely on mail and specialty pharmacies. Fein, Ph.D., All rights reserved.
For updated data on hospital-owned specialty pharmacies, see Chapter 3 of DCI's new 2024 Economic Report on U.S. As many of you know, hospitals and health systems have emerged as significant participants in the specialty pharmacy industry. I then highlight how hospitals steer prescriptions to their internal specialty pharmacies.
pharmacy industry—act as contract pharmacies for the hospitals and federal grantees that participate in the 340B program. Federal grantees are aligned primarily with the vertically intergated organizations' retail pharmacies, while hospitals rely on mail and specialty pharmacies. Fein, Ph.D., All rights reserved.
Below, I include links to publicly available comments from a diverse range of stakeholders, including 340B Health, the American Hospital Association, Biotechnology Innovation Organization, Community Oncology Alliance, National Association of Community Health Centers, and Pharmaceutical Research and Manufacturers of America.
For my first Drug Channels news roundup of 2021, I focus on two remarkable, must-read reports that provide extraordinary details about the hidden economics of our drug channel: The Center for Medicare & Medicaid Services’ new transparency rule discloses how much major insurers overpay hospitals for outpatient drugs.
Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. But Minnesotas report marks a valuable first step on the yellow brick road to the wonderful world of transparency. I suspect similar reports are gonna be popular. All rights reserved. This Feed is for personal non-commercial use only.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content